Addition of Induction Chemotherapy to Chemoradiation Improves Survival Outcomes Among Patients with Locally Advanced Cervical Cancer
According to a phase 3 trial, the addition of induction chemotherapy to standard chemoradiation significantly improved progression-free survival (PFS) and overall survival (OS) among patient with locally advanced cervical cancer.
Jonathan A. Ledermann, MD, University College London Hospitals NHS Foundation Trust, UK, presented the results from the GCIG INTERLACE trial at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer in San Diego, California.
Dr Ledermann and coauthors wrote that while patients with locally advanced cervical cancer receive chemoradiation, “many patients relapse and die from metastatic disease.”
In the GCIG INTERLACE trial, 500 patients with locally advanced cervical cancer were enrolled from 32 centers across 5 countries. Patients were randomized on a 1-to-1 basis to receive either chemoradiation alone or induction chemotherapy followed by chemoradiation. The primary end points of this study were PFS and OS.
The median follow-up duration was 64 months. The 5-year PFS rate was 73% in the induction chemotherapy arm vs 64% in the chemoradiation alone arm (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.46 to 0.91; P = .013). The 5-year OS rates were 80% and 72%, respectively (HR, 0.61; 95% CI, 0.40 to 0.91; P = .04). Grade ≥3 adverse events occurred in 59% of patients in the induction chemotherapy arm and 48% in the chemoradiation alone arm.
Dr Ledermann et al concluded, “Induction chemotherapy followed by [chemoradiation]…should be considered a new standard of care” for patients with locally advanced cervical cancer.” They also noted that this study “recruited patients from diverse health care settings demonstrating that [induction chemotherapy] followed by [chemoradiation] is feasible in all countries.
Source:
Ledermann JA, McCormack M, Gallardo Ríncon D, et al. A randomized, phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial. Presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancers; March 16-18, 2024. San Diego, California.
